ICP a RWA / Crypto on chain exchange

Hello everyone,

Tokenising Shares and RWAs on ICP with its vision of a decentralized, scalable blockchain ecosystem, ICP is uniquely positioned to revolutionize how we think about ownership, trading, and value exchange.

One untapped opportunity? Tokenized Real World Assets (RWAs) as a mechanism for holding shares, paired with a brokers market where crypto can seamlessly swap for shares and vice versa. Here’s why this could be a game-changer for ICP—and the broader blockchain space.

Tokenized Shares: Ownership Meets Blockchain Efficiency Imagine owning a piece of a company—say, a share of Tesla or a small business—represented as a token on ICP’s blockchain. Tokenizing RWAs like equity brings traditional assets into the digital realm, leveraging ICP’s speed, security, and low-cost transactions. Shareholders wouldn’t just hold a paper certificate or a line in a broker’s database; they’d have a verifiable, transparent, and programmable asset on-chain. This opens the door to fractional ownership, global accessibility, and instant settlement—things traditional stock markets can only dream of. ICP’s canister smart contracts could manage these tokens, embedding rules like voting rights or dividend distribution directly into the asset. No intermediaries, no delays—just pure, decentralized ownership.
A Brokers Market: Bridging Crypto and Shares Now, take it a step further: a decentralized brokers market built on ICP where users can trade these tokenized shares for cryptocurrencies (like ICP itself) or swap crypto for shares in real-time. Picture this: you hold ICP tokens, spot a tokenized share of a renewable energy startup, and swap your crypto for it instantly—no bank, no clearinghouse, just peer-to-peer value exchange. This market could run 24/7, unrestricted by traditional exchange hours, and be accessible to anyone with an internet connection. ICP’s scalability ensures it can handle the transaction volume, while its governance model could incentivize liquidity providers—think staking rewards for market makers. It’s a win-win: crypto holders diversify into RWAs, and traditional investors dip their toes into blockchain, all within one ecosystem.
Tax Efficiency: Keep Your Gains in the System Here’s a kicker: by keeping everything on-chain, you could defer taxes until you cash out to fiat. In many jurisdictions, swapping one asset for another (crypto for tokenized shares, or vice versa) isn’t a taxable event until you withdraw to traditional currency. So, you could trade, diversify, and grow your portfolio within ICP’s ecosystem without triggering a tax bill every step of the way. Only when you decide to exit to fiat—say, to your bank account—would you settle up with the taxman. It’s a built-in incentive to stay in the ecosystem, amplifying adoption and liquidity.
Why ICP? The Perfect Fit ICP’s architecture—its reverse gas model, high throughput, and ability to host complex dApps—makes it the ideal platform for this vision. Traditional blockchains like Ethereum might choke under the gas fees or scalability demands of a brokers market, while centralized exchanges carry counterparty risk. ICP sidesteps these issues, offering a decentralized, user-friendly foundation where tokenized RWAs and a trading ecosystem can thrive.
The Bigger Picture: Redefining Finance This isn’t just about shares or crypto—it’s about redefining how value moves in the digital age. Tokenized RWAs on ICP could extend beyond stocks to real estate, art, or even intellectual property, all tradable in a unified market. It’s a step toward a future where blockchain doesn’t just mimic traditional finance but leapfrogs it entirely

Let’s build it !

Kurt Nitsch

4 Likes

ICP is ideal for RWA, two of our portfolio companies are building two compliant products, one is live for sign up now https://xpm3z-7qaaa-aaaan-qzvlq-cai.icp0.io/ they are starting with tow yield tokens, one for fixed income and another is an index fund that tracks the top 30 stocks in the Egyptian exchange. Both funds are regulated and it has a kyc-kyb procedure in place supported by the regulator.

2 Likes

Very interesting :thinking: I suppose once launched they will bring onboard more stocks?

Also would the stocks be transferable NFTs 24/7 trading.

Looks and sounds like a great project.

Yes more stocks is definitely on the roadmap. For now we have an index fund that tracks 30 stocks. Are there any particular stocks you would like to see? We have a partnership with two of the biggest banks here and we can easily use their institutional accounts-liquidity to go for stocks. So far the stocks are not NFTs, they are modified icrc 2 tokens I believe

Glad to hear more stocks are on the roadmap! Your index fund tracking 30 stocks with those bank partnerships sounds like a solid setup—plenty of liquidity to play with there. Since you’re using modified ICRC-2 tokens, it’s a cool twist keeping things flexible.

As for stocks I’d love to see, how about these: Tesla (TSLA), Palantir Technologies (PLTR), The Trade Desk (TTD), CRISPR Therapeutics (CRSP), Coinbase Global (COIN), Amazon (AMZN), Advanced Micro Devices (AMD), Pinterest (PINS), and Block Inc. (SQ)?
Bigbearai (BBAI) and I
think… Beam Therapeutics (BEAM), Intellia Therapeutics (NTLA), and Recursion Pharmaceuticals (RXRX). They’re all about cutting-edge growth in AI, biotech, and blockchain, which could really boost the fund over the next few years. What do you reckon—any of these vibe with your plans?

2 Likes

I have to admit we did not have any plans for biotech, but definitely interesting. Thank you for the recommendation. Stocks are expected 4-5 months after launching the fixed income and index funds in a couple of weeks.

1 Like

AI’s relentless march paired with faster, beefier compute is setting biotech stocks up for a hell of a run. The old chokeholds—years-long drug discovery, insane R&D budgets—are starting to crack. Picture this: AI sifts through genomic haystacks and spits out drug targets in days, not decades. Protein folding, once a slog, now unfolds in hours thanks to tools like AlphaFold and the raw horsepower behind them. That’s not just a lab trick—it’s a lifeline for smaller biotech outfits that live or die by a single candidate. Less time from concept to clinic means less cash torched before they hit paydirt. Big pharma’s not sleeping either; they’re scooping up AI startups or rigging their own systems to stay ahead.
The tailwinds are real. Aging populations are ballooning—more knees giving out, more hearts ticking unevenly—and chronic diseases like diabetes or cancer aren’t slowing down. Biotech’s the tip of the spear, and AI’s sharpening it. Success rates could climb as treatments get personal—drugs tuned to your DNA, not some generic guess. Regulators might still drag their feet, and data privacy’s a ticking bomb, but the momentum’s undeniable. Market’s already sniffing it out—stocks tied to computational biology or genomics pop whenever a headline lands. Hype can overcook it, sure, but the bones of this are solid: AI plus compute equals faster wins, and biotech’s where the rubber meets the road

1 Like